GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syncom Formulation (India) Ltd (NSE:SYNCOMF) » Definitions » 6-1 Month Momentum %

Syncom Formulation (India) (NSE:SYNCOMF) 6-1 Month Momentum % : 31.19% (As of May. 11, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Syncom Formulation (India) 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-05-11), Syncom Formulation (India)'s 6-1 Month Momentum % is 31.19%.

The industry rank for Syncom Formulation (India)'s 6-1 Month Momentum % or its related term are showing as below:

NSE:SYNCOMF's 6-1 Month Momentum % is ranked better than
81.39% of 1107 companies
in the Drug Manufacturers industry
Industry Median: 0.83 vs NSE:SYNCOMF: 31.19

Competitive Comparison of Syncom Formulation (India)'s 6-1 Month Momentum %

For the Drug Manufacturers - Specialty & Generic subindustry, Syncom Formulation (India)'s 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syncom Formulation (India)'s 6-1 Month Momentum % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Syncom Formulation (India)'s 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Syncom Formulation (India)'s 6-1 Month Momentum % falls into.



Syncom Formulation (India)  (NSE:SYNCOMF) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Syncom Formulation (India)  (NSE:SYNCOMF) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Syncom Formulation (India) 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Syncom Formulation (India)'s 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Syncom Formulation (India) (NSE:SYNCOMF) Business Description

Traded in Other Exchanges
Address
207, Saket Nagar, Near Saket Club, Indore, MP, IND, 452018
Syncom Formulation (India) Ltd is in the business of pharmaceuticals. The company operates through three segments including manufacturing and dealings in Pharmaceutical drugs and formulations, Trading of commodities, and Renting of property. It manufactures and markets pharmaceutical formulation products in various dosage forms like tablets, capsules, liquids orals, liquids vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and Herbals. The company's product includes generic, antiviral, antidepressant, cough suppressant, electrolyte, histamine, estrogen, and much more. It generates maximum revenue through the Pharmaceutical drugs and formulations segment.

Syncom Formulation (India) (NSE:SYNCOMF) Headlines

No Headlines